The Online Investor
Healthcare M&A image Healthcare M&A » By The Online Investor Staff, updated Thu., Aug. 6, 3:37 PM Recent mergers and acquisitions in the Healthcare M&A category.

Slide #95. Emergent BioSolutions Inc. Cangene Corporation

Acquirer: Emergent BioSolutions Inc. (EBS)
Acquiree: Cangene Corporation (CNJ.CA)
Details: Cangene Corporation ("Cangene") (TSX: CNJ) today announced that the Ontario Superior Court of Justice issued a final order approving the Plan of Arrangement for the previously announced acquisition of Cangene by Emergent BioSolutions Inc. (NYSE: EBS). Under the court-approved Plan of Arrangement, Cangene shareholders will receive US$3.24 per share (C$3.561 per share) in cash, for an aggregate purchase price of US$222 million (approximately C$244 million2).

Emergent BioSolutions is a life sciences company. Co. is focused on preparedness and response products and solutions that address the following categories: Chemical, Biological, Radiological, Nuclear and Explosives; emerging infectious diseases; travel health; emerging health crises; acute/emergency care; and contract development and manufacturing. Co. also has a development pipeline consisting of a mix of both pre-clinical and clinical-stage product candidates, including Trobigard® a combination drug-device auto injector product candidate. In addition, Co. has a fully integrated molecule-to-market biologics CDMO business offerings (development services, drug substance and drug product).

EBS SEC Filing Email Alerts Service


Open the EBS Page at The Online Investor »

Emergent BioSolutions is a life sciences company. Co. is focused on preparedness and response products and solutions that address the following categories: Chemical, Biological, Radiological, Nuclear and Explosives; emerging infectious diseases; travel health; emerging health crises; acute/emergency care; and contract development and manufacturing. Co. also has a development pipeline consisting of a mix of both pre-clinical and clinical-stage product candidates, including Trobigard® a combination drug-device auto injector product candidate. In addition, Co. has a fully integrated molecule-to-market biologics CDMO business offerings (development services, drug substance and drug product).

EBS SEC Filing Email Alerts Service


Open the CNJ.CA Page at The Online Investor »

Company Name: 
Emergent BioSolutions Inc
Stock buyback: 
EBS buyback
Website: 
www.emergentbiosolutions.com
Sector: 
Biotechnology
Number of ETFs Holding EBS: 
42
Total Market Value Held by ETFs: 
$813.63M
Total Market Capitalization: 
$5.83B
% of Market Cap. Held by ETFs: 
13.95%
Company Name: 
Cangene Corp.
Website: 
www.cangene.com
Sector: 
Biotechnology
 

Quotes delayed 20 minutes


Healthcare M&A - Slide 95 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.